MONITORING PATIENTS WHO ARE STARTING #HEPATITIS C TREATMENT, ARE ON TREATMENT, OR HAVE COMPLETED #THERAPY

http://www.hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have

This section provides guidance on monitoring patients with chronic hepatitis C who are starting treatment, are on treatment, or have completed treatment. The section is divided into three parts: pretreatment and on-treatment monitoring, posttreatment follow-up for persons in whom treatment has failed to clear virus, and posttreatment follow-up for those who achieved a sustained virologic response (SVR; virologic cure).

Pharmacologic #Therapy for Type 2 #Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
http://annals.org/aim/article/2609290/pharmacologic-therapy-type-2-diabetes-synopsis-2017-american-diabetes-association

Pharmacologic Therapy for Type 2 Diabetes: Recommendations

Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacologic agent for the treatment of type 2 diabetes (A rating). Long-term use of metformin may be associated with biochemical vitamin B12 deficiency, and periodic measurement of vitamin B12 levels should be considered in patients treated with metformin, especially those with anemia or peripheral neuropathy (B rating). Providers should consider initiating insulin therapy (with or without additional agents) in patients with newly diagnosed type 2 diabetes who are symptomatic, have a hemoglobin A1c (HbA1c) level of 10% or greater, or have a blood glucose level of 16.7 mmol/L (300 mg/dL) or greater (E rating). If noninsulin monotherapy at the maximum tolerated dose does not achieve or maintain the HbA1c target after 3 months, adding a second oral agent, a glucagon-like peptide-1 (GLP-1)–receptor agonist, or basal insulin should be considered (A rating). For patients with type 2 diabetes who are not achieving glycemic goals, insulin therapy should be instituted without delay (B rating). A patient-centered approach should be used to guide the choice of pharmacologic agents (E rating).

Oral Direct-Acting Agent #Therapy for Hepatitis #C Virus Infection: A Systematic Review
http://annals.org/aim/article/2612232/oral-direct-acting-agent-therapy-hepatitis-c-virus-infection-systematic

Limitations:
Twenty-three studies had moderate risk of bias (10 were open-label single-group trials, 11 had limited information on concealment of the allocation scheme, and 5 had selective outcome reporting). All but 1 of the studies were industry-funded. Heterogeneity of interventions precluded pooling.